Polymorphous light eruption
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Polymorphous light eruption Classification and external resources | |
| ICD-10 | L56.4 |
|---|---|
| ICD-9 | 692.72 |
| DiseasesDB | 10327 |
| eMedicine | derm/342 |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Polymorphous light eruption (PLE), or polymorphic light eruption, is a skin complaint caused by sunlight. Symptoms include skin irritations, which may be itchy or painful, and are sometimes confused with hives. These irritations appear upon exposure to sunlight—sometimes as little as 15 minutes of exposure to the sun can bring onset of the condition—and may last from 1 to 7 days. Generally, PLE resolves without treatment; also, PLE irritations generally leave no scar. The cases of this condition are most common between the spring and autumn months in the northern hemisphere.
Typically, 10-20% of the population are affected. It is more common in females than in males. The condition can affect all ethnic groups and research suggests that 20% of patients have a family history of the complaint. Those suffering from PMLE usually do so by age 30.
The cause of PLE is not yet understood. It is thought to be due to a type IV delayed-type hypersensitivity reaction.
Experimental treatments
As of 2008 a company in Australia named Clinuvel Pharmaceuticals Limited is performing clinical trials with a melanocyte-stimulating hormone named melanotan (which they refer to as CUV1647) for polymorphous light eruption.[1]
References
External links
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
